Jakarta (Indonesia Window) – A total of 1,504,800 doses of ready-to-use COVID-19 vaccines produced by AstraZeneca arrived in Indonesia on Thursday night (June 10) at Soekarno-Hatta International Airport, Tangerang, Banten.

The vaccine was obtained through the COVAX Facility multilateral cooperation scheme.

"Thank God, tonight, Indonesia again received the AstraZeneca vaccine through the multilateral COVAX Facility as many as 1,504,800 doses," said Indonesian Foreign Minister Retno Marsudi in a press statement welcoming the arrival of the vaccine.

Earlier, on June 5, 2021, Indonesia had also received 313,100 doses of the AstraZeneca vaccine, which were also obtained from the COVAX Facility, she added.

With the arrival of the Astrazeneca vaccine on June 5 and 10, the total number of ready-to-use vaccine produced by British-Swedish company, that Indonesia received from the COVAX Facility for free, is 8,228,400 doses.

Overall, the total vaccines that have been received by Indonesia so far amounted to 93,728,400 doses, consisting of 84.5 million doses of Chinese Sinovac, 8,228,400 doses of AstraZeneca, and 1 million doses of Chinese Sinopharm.

"In addition, God willing, tomorrow afternoon, Friday (June 11) there will be another 1 million doses of vaccines from Sinopharm which will be used for the national vaccine program called gotong royong (mutual assistance)," said the foreign minister.

Retno noted that the three types of vaccines used in the COVID-19 vaccination program in the country, namely Sinovac, AstraZeneca, and Sinopharm, had obtained emergency use permits from the World Health Organization (WHO).

“All of them have obtained Emergency Use Listing (EUL) from WHO. This certainly confirms that the vaccines used in Indonesia have met international requirements in terms of quality, safety, and efficacy for use during the health emergencies," she said.

The foreign minister added that until now there are six types of vaccines that have obtained EUL from WHO, namely Sinovac, AstraZeneca, Sinopharm, Pfizer, Johnson & Johnson, and Moderna.

Reporting by Indonesia Window